News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc
(NQ:
XENE
)
39.25
+2.06 (+5.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Xenon Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Analyst Ratings for Xenon Pharmaceuticals
December 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
December 12, 2022
Via
Benzinga
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
Where Xenon Pharmaceuticals Stands With Analysts
November 28, 2022
Via
Benzinga
Analyst Sees This Epilepsy Player As 'M&A Sweet Spot'
October 19, 2022
Via
Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
October 11, 2022
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 06, 2022
Via
Benzinga
Analyst Ratings for Xenon Pharmaceuticals
August 29, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
November 28, 2022
Via
Benzinga
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
November 09, 2022
Biotech stocks were hammered Wednesday, including several that had good news.
Via
Investor's Business Daily
Earnings Scheduled For November 8, 2022
November 08, 2022
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Via
Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
August 11, 2022
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Via
Benzinga
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency
June 23, 2022
Via
Benzinga
Earnings Preview: Xenon Pharmaceuticals
November 07, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon...
Via
Benzinga
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
November 01, 2022
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends.
Via
InvestorPlace
Swing Trading Stock Watchlist For The Week Of Sept. 6
September 04, 2022
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.
Via
Talk Markets
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
August 29, 2022
Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
August 29, 2022
Upgrades
Via
Benzinga
Xenon Pharmaceuticals Shares Drop On Proposed Public Offering
June 22, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
October 19, 2022
Upgrades
Via
Benzinga
What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals
August 11, 2022
Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:
Via
Benzinga
Xenon Pharmaceuticals: Q2 Earnings Insights
August 09, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For August 9, 2022
August 09, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
August 08, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022
July 21, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
June 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All
June 23, 2022
The company had bullish results in seizure treatment. But it wasn't enough.
Via
Investor's Business Daily
US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony
June 23, 2022
Pre-open movers
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.